Comparison · NCT00744497-sae
Dasatinib vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dasatinib vs Placebo: serious adverse events. Trial comparisons, record NCT00744497-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00744497-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.501 | 0.465 | 0.536 | wilson | |
| Risk in group 2 | 0.419 | 0.384 | 0.454 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0819 | 0.0318 | 0.131 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.2 | 1.07 | 1.33 | log | |
| Odds ratio, group 1 over group 2 | 1.39 | 1.14 | 1.7 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Dasatinib than on Placebo | 12.2 | 7.61 | 31.5 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dasatinib | Participants received dasatinib, 100 mg, orally once daily plus docetaxel, 75 mg/m\^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily | 381 | 761 | EG001 |
| Group 2 | Placebo | Participants received placebo, given orally once daily, plus docetaxel, 75 mg/m\^2, given intravenously every 3 weeks as a 1-hour infusion, plus prednisone, 5 mg, given orally twice daily | 317 | 757 | EG000 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Day 1 up to 30 days post last dose of study therapy
Source ClinicalTrials.gov
Trial
- Title
- Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer
- NCT number
- NCT00744497
- Phases
- PHASE3
- Conditions
- Prostatic Neoplasms
- Interventions
- Placebo, Dasatinib, Docetaxel, Prednisone
- Lead sponsor
- Bristol-Myers Squibb
- Results first posted
- 2014-02-06
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00744497?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00744497-sae